Navigation Links
Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
Date:3/8/2012

ountries' governmental rules and regulatory authorities.

About Uremic Toxin Reduction Technology

Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for CKD patients) and Azodyl™ (veterinary formulation) consist of a combination of three specific probiotic microbial strains. The results of a randomized, double-blind, crossover, pilot scale clinical trial completed in 2010 provided encouraging preliminary evidence that the Company's technology could be effective when the formulation is taken together with the standard therapy according to individual patient conditions.

Forward-looking statements

This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in the current limited human trials or that data from patients enrolled in the study may not be useful or conclusive or sufficient to guide future development of Renadyl™. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to de
'/>"/>

SOURCE Kibow Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
4. LPBP Inc. - Re-filing certification of interim filings
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
8. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
9. Misonix Announces Interim Distribution Agreement for Italy
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... 19 Lightwave Logic, Inc. (OTC Bulletin Board: LWLG ... on the development of electro-optic polymer materials for applications ... today the addition of Anthony J. Cocuzza, PhD to ... in medicinal chemistry and brings a highly developed set ...
... -- What do Saturn and flowers have in common? ... easily recognizable in the natural world. Now, at an ... University of Massachusetts have created a unique set of ... will consistently assemble themselves into these and other complex ...
... FOLD ) announced today that Stephen Bloch, ... from the Company,s Board of Directors effective February 17, ... Amicus, board since 2004. About Amicus Therapeutics ... oral therapeutics known as pharmacological chaperones for the treatment ...
Cached Biology Technology:Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team 2Sophisticated nano-structures assembled with magnets 2Sophisticated nano-structures assembled with magnets 3
(Date:4/17/2014)... available in German . ... protection money demanded of him, he can expect his premises ... as fear of the consequences is enough to make restaurant ... birds, which lay their eggs in other birds, nests. If ... parasites take their revenge by destroying the entire nest. Consequently, ...
(Date:4/17/2014)... Yokahama IPCC meeting painted a stark warning on the ... has a greenhouse effect 32 times that of carbon ... that humic substances act as fully regenerable electron acceptors ... held in wetlands instead of being released to the ... is disrupted it may enter into a vicious cycle ...
(Date:4/17/2014)... Pine forests are chock full of wild animals and ... populations of fungi are churning away in the soil, ... , Despite the vital role these fungi play in ... A Stanford-led team of scientists has generated a genetic ... North America. The work was published this week in ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... friend," and rightly so. Consider, for example, that they never ... us when we arrive home, and provide comfort when we ... have worked with and lived next to humans, which some ... the 400 breeds and varieties are unique, but only one ...
... use of a robot to assist with the most ... patient,s risk of developing a rare but serious complication, ... edition of the Journal of Robotic Surgery. ... School at Houston statistically analyzed operative times, length of ...
... Harbor Laboratory (CSHL) professor David Jackson, Ph.D., and a team ... development of the maize plant, commonly known in the United ... understanding of how the different parts of maize arise--important information ... in the U.S. and a mainstay of the global food ...
Cached Biology News:Lessons from the Iditarod 2Lessons from the Iditarod 3Robotic surgery lowers risk of a rare but serious complication of gastric bypass 2Researchers find an essential gene for forming ears of corn 2
... The epitope recognized by ... of isoform 5 of human ... AAH19917.1 (GeneID 9444). The ... isoforms 1, 2, 3, 4, ...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
...
See product name for description....
Biology Products: